Veru to Present at Upcoming Healthcare Investor Conferences in New York
September 27 2018 - 5:00PM
Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical
company, today announced that the company’s Chairman, President and
Chief Executive Officer, Dr. Mitchell Steiner, will present an
overview of the company’s development programs at the following
investor conferences.
Presentation details:
Event: |
|
|
|
|
|
Cantor Fitzgerald
Global Healthcare Conference |
|
Date: |
|
|
|
|
|
Monday, Oct. 1,
2018 |
|
Time: |
|
|
|
|
|
8:55 a.m. EDT |
|
Location: |
|
|
|
|
|
InterContinental New
York Barclay Hotel |
|
|
|
|
|
|
|
|
|
Event: |
|
|
|
|
|
Ladenburg Thalmann 2018
Healthcare Conference |
|
Date: |
|
|
|
|
|
Tuesday, Oct. 2,
2018 |
|
Time: |
|
|
|
|
|
4 p.m. EDT |
|
Location: |
|
|
|
|
|
Sofitel New York
Hotel |
|
A webcast of the Cantor Fitzgerald presentation will be
available at www.verupharma.com. Listeners are encouraged to visit
the web site at least 10 minutes prior to the start of the
presentation to register, download and install any necessary
software. The presentation will be archived and accessible on the
web site for at least 90 days.
About Veru Inc.Veru Inc. is an oncology
and urology biopharmaceutical company developing novel medicines
for prostate cancer and prostate cancer supportive care as well as
near term specialty pharmaceuticals to address significant unmet
needs in urology.
The Veru prostate cancer pipeline includes
zuclomiphene citrate (also known
as VERU-944, cis-clomiphene) and VERU-111
(bisindole). Zuclomiphene citrate is an estrogen receptor agonist
being evaluated in a Phase 2 trial to treat hot flashes, a common
side effect caused by hormone treatment for men with advanced
prostate cancer. VERU-111 is an oral, next-generation,
first-in-class agent that targets alpha and beta subunits caused by
cells to form cellular microtubules to treat castration and novel
androgen blocking agent (abiraterone or enzalutamide) resistant
metastatic prostate cancer that Veru expects to enter
Phase 1/2 development in late 2018.
Veru is also advancing four new drug formulations in its
specialty pharmaceutical pipeline addressing unmet medical needs in
urology. Tamsulosin DRS granules and Tamsulosin XR capsules are
formulations of tamsulosin that avoid the “food effect” in
currently marketed formulations of the drug, allowing for
potentially safer administration and improved patient compliance
(NDA filing expected in 2019). Veru is also developing
Tadalafil/Finasteride combination tablets for inhibition of both
phosphodiesterase type 5 (PDE5) and 5-alpha-reductase to shrink an
enlarged prostate, treat symptoms of benign prostatic hyperplasia
and to treat erectile dysfunction (NDA filing expected in 2019).
Finally, Solifenacin delayed release granules are a formulation of
a selective M3 muscarinic receptor antagonist for the treatment of
overactive bladder in patients who have difficulty with swallowing
tablets (NDA filing expected in 2019).
Veru’s currently marketed products include the PREBOOST®
medicated individual wipe for the prevention of premature
ejaculation and the FC2 Female Condom®. The Female Health Company
Division markets the FC2 Female Condom® in the global public health
sector to improve the lives, health and well-being of women around
the world. To learn more please visit www.verupharma.com.
Contact:Kevin Gilbert 786-322-2213
Veru (NASDAQ:VERU)
Historical Stock Chart
From Mar 2024 to Apr 2024
Veru (NASDAQ:VERU)
Historical Stock Chart
From Apr 2023 to Apr 2024